An interventional study of Sitagliptin and BeiDouGen in Polycystic Ovarian Syndrome, sponsored by Peking University Third Hospital. Recruiting at 1 site in China. Open to female participants aged 20 Years to 40 Years. Per ClinicalTrials.gov, last updated 2024-09-19.
Sponsored by Peking University Third Hospital · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 13 studies in Polycystic Ovary Syndrome by Peking University Third Hospital — 7 open to participants now, 7 under way, none of them phase 3. Polycystic Ovary Syndrome · Peking University Third Hospital.
Among the 13 studies in Polycystic Ovary Syndrome by Peking University Third Hospital, this one is the 6th largest by planned enrollment of the 12 interventional ones that give a count, is one of 2 that started in 2024, is one of 11 with no phase, and was the 8th registered.
959 studies on the registry are indexed under Polycystic Ovary Syndrome; 176 are open to participants now.
Browse Polycystic Ovary Syndrome studies →7 of the 13 studies in Polycystic Ovary Syndrome by Peking University Third Hospital are open now, in 1 country. Recruiting first, the newest first:
Peking University Third Hospital · Sites in China
Ages 18–40 · Women only
Peking University Third Hospital · Sites in China
Ages 18–40 · Women only
Peking University Third Hospital · Sites in China
Ages 20–40 · Women only
Peking University Third Hospital · Sites in China
Ages 20–40 · Women only
Peking University Third Hospital · Sites in China
Ages 18–40 · Women only
By country, each count listing its studies:
Of the 120 Polycystic Ovary Syndrome studies recruiting now, 11 (9%) set no upper age limit and 106 (88%) stop at 75 or younger; 23 take children under 18; 41 take healthy volunteers.
This study: 20 Years to 40 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
13 studies; the count open now beside each. This study's row is marked.
First in 2015; this study’s year is marked. 2 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 300 is above the median of 70 across 700 interventional studies indexed under Polycystic Ovary Syndrome.
Median enrollment 255 across the 12 interventional studies, 733 across the 1 observational. Of the 4 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Peking University Third Hospital is the lead sponsor of 755 studies on the registry; 275 are open to participants now.
1 of the studies in Polycystic Ovary Syndrome by Peking University Third Hospital that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06775093Peking University Third HospitalEffects of GLP-1RAs on Reproductive Outcomes in PCOS and Obesity | 2026-12-31 |
Add it to your calendar (.ics) → With an account.
Among the 13 studies in Polycystic Ovary Syndrome by Peking University Third Hospital, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study will be carried out under the guidance of professional doctor, patients with PCOS will be treated with Sitagliptin or BeiDouGen capsule or both two to assess their ovarian function and reproductive outcomes, and compare the effect of different treatment methods, which will provide the basis for PCOS intervention strategy and related research
Subject Recruitment and Grouping This study adopts an open-label randomized controlled trial design. We plan to recruit a total of 300 patients with polycystic ovary syndrome (PCOS) by introducing the purpose, benefits, and risks of the study to patients in medical or examination units. PCOS patients who meet the inclusion criteria and do not meet the exclusion criteria will be registered and given a questionnaire by the research staff after signing the informed consent form. Physical and blood examinations will be conducted, and electronic randomization will be performed using the Redcap platform.
Intervention Measures After signing the informed consent form, enrolled patients will be randomly assigned to the Sitagliptin intervention group, the Bei Dou Gen intervention group, or the combination therapy group of Sitagliptin and Bei Dou Gen. Before enrollment, all three groups will undergo baseline assessments including blood routine, liver and kidney function, blood lipids, endocrine hormones, gynecological ultrasound, liver ultrasound, and physical examinations.
For participants in the Sitagliptin intervention group, Sitagliptin will be administered orally at a dose of 100 mg once daily for a treatment period of three months. Participants in the Bei Dou Gen intervention group will receive Bei Dou Gen capsules orally at a dose of 60 mg twice daily for a treatment period of three months. Participants in the combination therapy group will receive both Sitagliptin at a dose of 100 mg once daily and Bei Dou Gen capsules at a dose of 60 mg twice daily for a treatment period of three months.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Diagnosed with PCOS according to the Rotterdam criteria: Diagnosis of PCOS can be made if two out of the following three criteria are met: (1) Oligoovulation or anovulation, (2) Clinical or biochemical signs of hyperandrogenism, (3) Polycystic ovaries on ultrasound examination.
Patients who are regularly followed up at our clinic. No participation in other research projects currently or in the past 3 months.
Exclusion Criteria:
Exclusion criteria (any of the following criteria met will result in exclusion):
Pregnant, lactating, or women. Taking weight loss medications or undergoing weight loss surgery in the past 3 months or currently.
Food allergies. Other diseases that may cause hyperandrogenism or ovulation abnormalities (e.g., Cushing's syndrome, non-classical congenital adrenal hyperplasia, tumors secreting androgens in the ovaries or adrenal glands, functional hypothalamic amenorrhea, thyroid diseases, hyperprolactinemia, premature ovarian insufficiency, etc.).
Use of insulin, hypoglycemic drugs, or beta-blockers in the past 3 months. Patients with chronic diseases such as hypertension, gout, hyperuricemia, diabetes, etc., requiring regular medication.
Use of , anti-androgenic drugs, oral , ovulation-inducing drugs, weight loss drugs, or other medications affecting hormone levels, appetite, and carbohydrate metabolism in the past 2 months.
Patients with liver cirrhosis or various severe liver diseases ( and/or aspartate aminotransferase exceeding 3 times the ), patients with abnormal renal function (serum creatinine exceeding the upper limit of normal), patients with kidney disease or other diseases requiring control of protein intake.
Patients currently or previously with severe cardiovascular and cerebrovascular diseases that may interfere with the normal conduct of the trial (such as heart failure, myocardial infarction, cerebral infarction, acute myocarditis, severe arrhythmias, patients undergoing interventional therapy, etc.).
Patients currently with severe gastrointestinal diseases such as gastrointestinal ulcer bleeding, chronic diarrhea, or who have undergone gastrointestinal resection surgery, which may affect nutrient absorption.
Patients with infectious diseases such as e antigen-positive, active pulmonary tuberculosis, or .
Cancer patients or those who have received radiation and chemotherapy within the past five years.
Patients with any psychological or psychiatric disorders requiring medication, including epilepsy patients or those undergoing antiepileptic treatment, patients using antidepressants, etc.
Daily alcohol consumption exceeding 15g. Smoking habit
-
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
100mg/day Sitagliptin by oral for 3 months detail:1 piece(100mg) at morning
Drug: Sitagliptin
120mg/day BeiDouGen capsule by oral for 3 months detail:2 piece(30mg) at morning and night
Drug: BeiDouGen
100mg/day Sitagliptin+120mg/day BeiDouGen capsule by oral for 3 months detail:1 piece(100mg) Sitagliptin and 2 piece(30mg) BeiDouGen capsule at morning 2 piece(30mg) BeiDouGen capsule at night
Drug: Sitagliptin+BeiDouGen
100 mg QD for 3 month
Also known as: brand name:Jie Nuo Wei
60 mg BID for 3 month
Also known as: brand name:Kang xin
Drug page: SitagliptinStudies of SitagliptinSitagliptin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.
100 mg Sitagliptin QD plus BeiDouGen 60 mg BID for 3 month
Also known as: brand name:Jie Nuo Wei and Kang xin
Clinical pregnancy rate
the pregnancy situation among volunteers
Time frame: through study completion, an average of 2 year
DHEA
dehydroepiandrosteron in serum during menstruation period
Time frame: before and after intervention(3 month)
total testosterone
total testosterone in serum during menstruation period
Time frame: before and after intervention(3 month)
FAI
Free testosterone index calculated by total testosterone and SHBG
Time frame: before and after intervention(3 month)
LH/FSH
the rate between LH and FSH
Time frame: before and after intervention(3 month)
ovarian volume
the size is measured by ultrasound
Time frame: before and after intervention(3 month)
number of antral follicles
the number is is measured by ultrasound during menstruation period
Time frame: before and after intervention(3 month)
Number of retrieved eggs
the number is observed during the surgery
Time frame: after intervention(3 month)
number of mature eggs (MII)
observed the state of oocytes during the IVF laboratory
Time frame: after intervention(3 month)
fertilization rate
observed the state of oocytes during the IVF laboratory
Time frame: after intervention(3 month)
number of usable embryos,
observed the state of embryos during the IVF laboratory
Time frame: after intervention(3 month)
number of high-quality embryos
observed the state of embryos during the IVF laboratory
Time frame: after intervention(3 month)
GLP-1 levels
measure it in the serum
Time frame: before and after intervention(3 month)
fasting glucose
measured by glucometer
Time frame: before and after intervention(3 month)
OGTT
measured by glucometer
Time frame: before and after intervention(3 month)
HOMA index
calculated by glucose and INS
Time frame: before and after intervention(3 month)
Plan to share: No
No publications or documents are linked to this record.
Started Aug 2024 (actual). Primary completion is estimated for Jul 2028, 46 months after the start.
Of 205 non-industry interventional studies with no phase under Polycystic Ovary Syndrome, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 37. This study's planned 46 months is above that.
Counting every sponsor, half of 220 studies reached it within 17 months; a quarter within 7 and three quarters within 37.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Sitagliptin
Peking University Third Hospital →